Cingulate Inc. (CING) company profile

Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing and advancing next-generation pharmaceutical products. The company utilizes its proprietary Precision Timed Release drug delivery platform technology, which incorporates an Erosion Barrier Layer designed to release drug substances at specific, pre-defined intervals in once-daily, multi-dose tablets. Its pipeline centers primarily on the treatment of Attention Deficit/Hyperactivity Disorder and anxiety. Candidate medications include CTx-1301 and CTx-1302 for pediatric, adolescent, and adult patients diagnosed with Attention Deficit/Hyperactivity Disorder, alongside CTx-2103 for the treatment of generalized anxiety disorder.

The company operates in the United States and has secured patent coverage across European territories, including the United Kingdom. Cingulate collaborates with external contract development, manufacturing, and commercial service partners with operational facilities in locations such as Gainesville, Georgia. Its principal executive offices and headquarters are located in Kansas City, Kansas.

Summary of the business section of Cingulate's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price per Unit is $6.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“One such fee waiver is available for applicants that are small businesses, meaning the applicant (including any affiliates) employs fewer than 500 employees, does not have an approved marketing application for a product that has been introduced or delivered for introduction into interstate commerce, and is submitting its first marketing application.”